175 related articles for article (PubMed ID: 21906628)
1. Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.
Hakki M; Drummond C; Houser B; Marousek G; Chou S
Antiviral Res; 2011 Nov; 92(2):313-8. PubMed ID: 21906628
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Bigley TM; Reitsma JM; Terhune SS
J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
4. Conserved domains and structure prediction of human cytomegalovirus UL27 protein.
Hantz S; Couvreux A; Champier G; Trapes L; Cotin S; Denis F; Bouaziz S; Alain S
Antivir Ther; 2009; 14(5):663-72. PubMed ID: 19704169
[TBL] [Abstract][Full Text] [Related]
5. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
Chou S; Marousek GI; Senters AE; Davis MG; Biron KK
J Virol; 2004 Jul; 78(13):7124-30. PubMed ID: 15194788
[TBL] [Abstract][Full Text] [Related]
7. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
Chou S; Hakki M; Villano S
Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
[TBL] [Abstract][Full Text] [Related]
8. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
[TBL] [Abstract][Full Text] [Related]
9. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
Reitsma JM; Terhune SS
Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
12. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
14. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.
Reitsma JM; Savaryn JP; Faust K; Sato H; Halligan BD; Terhune SS
Cell Host Microbe; 2011 Feb; 9(2):103-14. PubMed ID: 21320693
[TBL] [Abstract][Full Text] [Related]
15. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
[TBL] [Abstract][Full Text] [Related]
16. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Chou S; Watters M; Sinha R; Kleiboeker S
Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
[TBL] [Abstract][Full Text] [Related]
17. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
19. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
Chou S; Marousek GI
Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
[TBL] [Abstract][Full Text] [Related]
20. Frequent pUL27 Variations in HIV-Infected Patients.
Mirarab A; Mohebbi A; Moradi A; Javid N; Vakili MA; Tabarraei A
Intervirology; 2016; 59(5-6):262-266. PubMed ID: 28402975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
